Andi Marmor, MD, MSEd Professor of Pediatrics, UCSF

Slides:



Advertisements
Similar presentations
Use of Medications in Asthma Cyril Grum, M.D. Department of Internal Medicine *Based on the University of Michigan Guidelines for Clinic Care and the National.
Advertisements

Cases from Aug 2014 Cases from Aug 2014 Ryan Padrez & Patrick Peebles 9/10/14.
May 20, Definition Involves bronchial airways, not lung tissue Characterized by REVERSIBLE narrowing Peribronchial muscle spasm Mucous production,
AsthmaAsthma is a condition characterized by paroxysmal narrowing of the bronchial airways due to inflammation of the bronchi and contraction of the bronchial.
WHEEZING AND ASTHMA Effective management of continuing symptoms Dr Duncan Keeley.
Pediatric Asthma: Navigating Through Guidelines and Black Boxes Vinit K. Mahesh, M.D.
Review of authorization criteria in PDL drug classes Nicole N. Nguyen, PharmD Senior Clinical Pharmacist Health Care Services September 24, 2014.
Asthma in Schools Kathleen Kelly Shanovich, MS, RN, CPNP UW School of Medicine and Public Health Pediatric Allergy & Asthma March 11, 2015.
Chronic Disease Management in General Practice – Sample Assessment.
Global Initiative for Asthma (GINA) What’s new in GINA 2015?
Asthma Diagnosis Prescribing Acute Management Tracey Bradshaw Respiratory Consultant RIE.
1 British Guideline on the Management of Asthma BTS/SIGN British Guideline on the Management of Asthma, May 2008 Introduction Diagnosis Non-pharmacological.
Inhaled corticosteroids in preschool asthmatic children
Component 3: Pharmacologic Therapy n Asthma is a chronic inflammatory disorder of the airways. n A key principle of therapy is regulation of chronic airway.
Paediatric Asthma Maria Tracey Paediatric Pharmacist Jane Davis Paediatric Clinical Nurse Specialist CF/Respiratory Royal Alexandra Hospital Paisley.
Asthma Management Fine Tuning  Maximum control with minimum medication  Start with mild asthma and work up the scale (BTS/SIGN 2004)
Karen Homan NHS Bedfordshire
A PLAN TO IMPROVE ASTHMA CARE
Bronchial Asthma  Definition  Patho-physiology  Diagnosis  Management.
MANAGEMENT OF ASTHMA 6 Penaflor, Dominic Quinto, Milraam Ramos,Josefa Victoria Sicat, Gracie Suaco, David Tio- Cuizon, Jeremiah Valenzuela, Virginia Lou.
Bronchial Asthma  Definition  Patho-physiology  Diagnosis  Management.
Assessing Control & Adjusting Therapy in Youths > 12 Years of Age & Adults *ACQ values of 0.76–1.4 are indeterminate regarding well-controlled asthma.
AHEAD COSMOS and COMPASS Studies. The AHEAD Study.
Component 4 Medications.
Asthma Management and the Allergist: Better Outcomes at Lower Cost.
ASTHMA UPDATE Chad Fowler, M.D. 10/27/04. Asthma: Why do we care? It’s common: Affects million persons in U.S. Most common chronic disease of childhood:
Classification of Chronic Asthma Severity on Treatment Domains/EstimatesIntermittentPersistent Mild to Moderate Severe** Daytime symptoms MonthlyWeeklyDaily.
Food and Drug Administration Division of Pulmonary and Allergy Drug Products Summary Comments - Orally Inhaled and Intranasal Budesonide and Fluticasone.
Component 4 Medications. Key Points - Medications  2 general classes: – Long-term control medications – Quick-Relief medications  Controller medications:
Wendy Pigg Practice support Pharmacist/Independent Prescriber
Overview of Changes to the NAEP Asthma Guidelines Breathe California’s Clinical Asthma Collaborative Susan M. Pollart, MD, MS University of Virginia Family.
Tiotropium Bromide as an Adjunct Therapy to Inhaled Corticosteroids in the Treatment of Adults with Chronic Asthma Kevin Dennis Pacific University School.
Pharmacologic Treatment Of Asthma 1 د. ميريانا البيضة.
Respiratory medication use in Australia 2003–2013: Treatment of asthma and COPD AIHW: Correll PK, Poulos LM, Ampon R, Reddel HK and Marks GB. Published.
LSU Journal Club Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD WISDOM study H. Magnussen MD, et al. Nisha Loganantharaj, PGY1 April 21,
Prescribing for patients with COPD Evidence Update Emma Blanden- Pharmacist.
Management of stable chronic obstructive pulmonary disease (2) Seminar Training Primary Care Asthma + COPD D.Anan Esmail.
Dr Mazen Qusaibaty MD, DIS / Head Pulmonary and Internist Department Ibnalnafisse Hospital Ministry of Syrian health – Dr Mazen.
Clinical Applications of Spirometry for Pediatric Asthma
Safety of long-acting β-agonists for the treatment of asthma : clearing the air 장 나 은 Gustavo J Rodrigo, Jose A Castro-Rodrıguez Thorax 2012;
Budesonide/Formoterol in a Single Inhaler for Maintenance and Relief in Mild-to-Moderate Asthma* A Randomized, Double-Blind Trial Klaus F. Rabe, MD, PhD;
Wheeze and Asthma Key Facts and Updates Dr Reena Bhatt, Paediatric Darzi Fellow in Asthma.
RI Asthma Control Program: Comprehensive Asthma Care
GLOBAL INITIATIVE FOR ASTHMA (GINA) TEACHING SLIDE SET
Pharmacology of Anti- Asthmatic Medications
Jessica Case study.
Eileen G. Holland, Pharm.D., BCPS Associate Professor
Therapeutics 2 Tutoring: Asthma
Dysautonomia Formulary
Global Initiative for Asthma (GINA) Teaching slide set 2017 update
Research where it is most needed National Respiratory Strategy
COPD By Alaina Darby.
Fever and Antipyretic use in children Clinical report AAP 2011
Chapter 11 RES 219 Pharmacology
Copyright © 2015 by the American Osteopathic Association.
Monitoring asthma in primary care
Asthma By Alaina Darby.
Asthma/ Wheeze and children
Global Initiative for Asthma (GINA) What’s new in GINA 2015?
Systemic Procaterol (Meptin) as a CONTROLLER for Asthma
The Role of the Primary Care Physician in Helping Adolescent and Adult Patients Improve Asthma Control  Barbara P. Yawn, MD, MSc  Mayo Clinic Proceedings 
The Modern Management of Asthma: Getting it right Part 2
Evidence-Based Asthma Guidelines
Global Initiative for Asthma (GINA) What’s new in GINA 2015?
The efficacy and safety of omalizumab in pediatric allergic asthma
The Aerosol Drug Management Improvement Team
Prescribing Update - Respiratory July 2019
Introduction Project At Crown Street Surgery:
Presentation transcript:

What’s New (and What Isn’t) in Asthma Management San Francisco Asthma Network Forum 2016 Andi Marmor, MD, MSEd Professor of Pediatrics, UCSF Zuckerberg San Francisco General Hospital Sept 21, 2016

Questions for this talk How should asthma be classified at acute and preventive visits? Do inhaled steroids make kids short? Can inhaled steroids be used intermittently? Are long-acting β-agonists safe? Can ICS/LABA be used for rescue? Does acetaminophen lead to asthma?

Case Presentation: Camellia 5 yo girl here for her an asthma follow-up visit, 1 month after her first hospitalization Mom is very concerned that she got “steroids” and does not want her to get all of the problems she’s heard about on the news You note that Camellia got PO dexamethasone X2 in the hospital, and was D/C’d on (QVAR) 40, 1 puff BID

What about side effects?

What is an advantage of dexamethasone over prednisone? Dexamethasone is more effective for lower airway inflammation Dexamethasone has a longer half-life than prednisone Dexamethasone can be given IM or IV if the child can’t take it PO Dexamethasone syrup tastes better than prednisone syrup

Dexamethasone vs prednisone Half-life: 12-24 hours Total dose studied: 6mg/kg over 5 days 2mg/ kg x 1, 1 mg/kg x 4 days PO syrup: 15 mg/5ml Bitter taste in some formulations Half-life: 36-72 hrs Equivalent dose: 1.2 mg over 5 days 0.6mg/kg x 2 doses IV formulation: 4mg/ml IV form well-tolerated when given PO Better compliance with 2 doses, and equal efficacy

What is an advantage of dexamethasone over prednisone? Dexamethasone is more effective for lower airway inflammation Dexamethasone has a longer half-life than prednisone Dexamethasone can be given IM or IV if the child can’t take it PO Dexamethasone syrup tastes better than prednisone syrup

Camellia’s Asthma Visit Continues Daytime/exercise: Using albuterol 2-3x/week during PE Nighttime: Wakes up at night 2x/per week, uses albuterol ED/hosp: 1 hosp and 1 exacerbation requiring PO steroids Meds: Using her Qvar daily, as prescribed 40 mcg BID = low dose

Without looking at the guidelines, how would you classify Camellia’s asthma? Moderate persistent asthma Severe persistent asthma Not well-controlled asthma Mild intermittent asthma Pneumonoultramicroscopicsilicovolcanoconiosis the longest word ever to appear in an English language dictionary., factitious name for silicosis

NHLBI Asthma Classification Assess SEVERITY in patient not currently on controller medication Assess CONTROL in patients currently on controller medication Treatment is based on classification of severity or control Initiate therapy based on severity Modify therapy based on control

Simplified version: Rule of 2’s ≥ 2 daytime /exercise symptoms/ week or ≥ 2 episodes of SABA use/week or ≥ 2 nighttime awakenings/month or ≥ 2 systemic corticosteroids or hospitalizations in last year _____________________________________ = PERSISTENT OR NOT WELL-CONTROLLED ASTHMA

Simplified version: Rule of 2’s ≥ 2 daytime /exercise symptoms/ week or ≥ 2 episodes of SABA use/week or ≥ 2 nighttime awakenings/month or ≥ 2 systemic corticosteroids or hospitalizations in last year _____________________________________ = PERSISTENT OR NOT WELL-CONTROLLED ASTHMA Step up to next level of care

EPR-3 (8/28/07): p296-304, 306

What about side effects?

Inhaled Corticosteroids: Effective? YES

Inhaled Corticosteroids: Safe? Daily use of ICS in kids associated with a small but statistically significant decrease in growth velocity in the 1st year of treatment Systemic effects related to absorption through lung epithelium not GI tract Growth effects seen in long-term trials are Mild (<1cm height loss) but permanent Dose-dependent Steroid-dependent (in some studies) Delivery device-dependent (smaller molecules = increased risk) Zhang 2014, Pruteanu 2013, Loke 2015, Wolfgram 2015

Principles for safe use of ICS Use lowest dose to achieve control Choose most effective molecule with least bioavailability fluticasone, mometasone, flunisolide > budesonide or beclomethasone The Next Generation: Ciclesonide Pro-drug activated in lung epithelium Preliminary studies confirm safety and efficacy Dosing for pediatric patients not yet established Zhang 2014 Kramer 2013

What about leukotriene receptor antagonists??

LTRA’s: Recommendations Inhaled corticosteroids are the preferred therapy (most effective, and cost-effective) for adult and pediatric persistent asthma Consider LTRA only for patients with mild persistent asthma in whom poor adherence or concern for side effects preclude the use of ICS. My consider as a 2nd-line adjunct to daily ICS in patients with mild breakthrough symptoms Chauhan 2014, Wang, 2011

Case Continued You decide to switch Camellia to Fluticasone, and increase her to a moderate dose (110mcg, 1 puff BID) You explain the risks and benefits of ICS and the importance of asthma control As you are finishing up the visit, mom asks “Why can’t she just take her inhaled steroid when she gets sick?”

Which of these regimens would be appropriate for this child? Use of ICS during exacerbations only Increasing dose of ICS during exacerbations Increasing frequency of ICS during exacerbations None of the above

Summary of evidence: intermittent ICS (during exacerbations only) Intermittent ICS superior to placebo Including preschoolers with intermittent wheeze Growth suppression similar to placebo Daily ICS superior to intermittent Increased risk of growth suppression in kids Chong, 2013; Kaiser 2016, Chauhan 2013

A few notes of caution… Patients enrolled generally had mild persistent or “episodic” asthma All of these trials included a run-in period of daily ICS The “rescue” dose was 2-3 times higher than daily dose

What about increasing DOSE of ICS during exacerbations? Adults: Meta-analysis showed no benefit to adding extra doses to daily ICS (Kew, 2016) Kids: One RCT: No advantage to adding rescue dose over daily dose (Martinez ,2011)

Martinez, 2011 Daily Combined Rescue Placebo

Which of these regimens would be appropriate for this child? Use of ICS during exacerbations only Increasing dose of ICS during exacerbations Increasing frequency of ICS during exacerbations None of the above She doesn’t have episodic or mild persistent asthma Why?

Recommendations for “Rescue” ICS: Consider when asthma is mild persistent or well-controlled on low-dose ICS and: Infrequent, mild exacerbations with viral prodrome Documented ability to take meds as instructed Reason not to stay on daily ICS (eg: growth concerns) “Rescue” dose should be moderate or high-dose There is no evidence for benefit of adding extra doses of ICS to daily ICS during exacerbations Also talk about other ways to reduce side effects from steroids: lowest effective dose, use of spacer, ciclesonide, etc

Camellia’s Follow-up Visit Camellia goes home on moderate-dose fluticasone after discussion of risks/benefits 3 mo later she comes to urgent care with an exacerbation requiring PO steroids Since her last visit: She is using her fluticasone reliably and correctly Still using her albuterol 3x/week during PE Wakes up at night twice per week = NOT well-controlled

EPR-3 (8/28/07): p296-304, 306

BLACK BOX WARNING? Wait a minute… Apparently adding a long-acting bronchodilator (LABA) is the next step But what about the BLACK BOX WARNING?

Rationale for FDA Warning Black box warning issued by FDA on all preparations containing LABA in May, 2006 SMART study: Clinical trial in adults, most on LABA ALONE Increased risk asthma-related death (13/13,176 vs 3/13,179) Recent meta-analyses (Salpeter, 2006; Rodrigo, 2009) found differences smaller but still statistically significant in kids Most recent review: Peters 2016

Are LABA’s effective? Studies in adults consistently show better asthma control with lower total steroid dose when LABA added Previous studies in kids showed benefit, but a recent meta-analysis failed to show benefit Recommendations: Adults: first line adjunct to ICS in patients poorly controlled on low-dose ICS Children <5: Off-label use only 5-12: consider in patients poorly controlled on mod dose ICS Open discussion with family about risks/benefits Chauhan, 2015

ICS/LABA combination inhalers Symbicort Budesonide/formoterol Advair: Fluticasone/salmeterol Dulera Mometasone/formoterol

Case Continued You start Camellia on the ICS/LABA combo covered by her insurance plan, with a plan to step back down to ICS One month later, she remains well-controlled However, her mother wonders if she can use her combo inhaler for rescue rather than also carrying her albuterol around

Using extra doses of a combination ICS/LABA for rescue is Supported by evidence from RCT’s Currently FDA approved for children FDA approved for adults but not for kids Totally nuts

Rationale: Combination ICS/LABA Inhalers for Rescue Formoterol (not salmeterol) has an onset of action (~5 min) similar to albuterol, with longer duration Benefits might include Ability to titrate ICS dose up during exacerbation Single inhaler for control and rescue Potential for better control with less total ICS

Evidence: ICS/LABA Inhalers for Control + Rescue Adults: Several recent trials (Rabe 2006, Bousquet 2007, Papi 2015) and 2 meta-analyses (Cates 2013, Kew 2013) ICS/LABA for rescue -> decreased use of SABA, fewer exacerbations compared to ICS alone or ICS/LABA control only Lower total ICS dose when compared to high daily dose ICS

Evidence in Kids: ICS/LABA for Control + Rescue RCT of 341 kids poorly controlled on ICS alone High-dose budesonide Bud/form + SABA rescue Bud/form control and rescue (Bisgaard, 2006)

Using extra doses of a combination ICS/LABA for rescue is Supported by evidence from RCT’s Currently recommended for children Recommended for adults but not for kids Totally nuts Not an FDA-approved indication So, why aren’t we all doing this?

Recommendations ICS/LABA inhalers are not currently licensed for rescue use in either children or adults… Benefits include better control with less ICS when compared to higher dose ICS

Questions for this talk How should asthma be classified at acute and preventive visits? SEVERITY in patients not on controller, CONTROL in patients on controller Do inhaled steroids make kids short? Yes, but not by much Can inhaled steroids be used intermittently? Yes, in select patient, at 3x normal doses Are long-acting β-agonists safe? Probably, but they should be used with caution Can ICS/LABA be used for rescue? Formoterol/ICS combo effective, but not approved for this indication

Camellia Camellia sinensis = “tea plant” Evergreen shrub originating in Asia Produces black, green oolong and white teas Ancient physicians in India and China used it as a treatment for asthma The bronchodilator theophylline was derived from C. sinensis in 1888